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Introduction
Different types of pathogenic variants in genes can cause genetic diseases. Most of them are missense variants that affect the coding region of genes. This type of variants consists in a change of aminoacid that alters or impairs the normal function of the resultant protein, therefore causing the disease phenotype. Until recently it was considered that pathogenic variants were always present in all the cells of an individual. However, it is increasingly evident that all individuals are actually complex mosaics composed of multiple genotypes acquired post-zygotically, and that in many cases this can produce a pathogenic effect. In the later cases, the variant must be present in the appropriate cell types and achieve a threshold in the number of cells affected so that the disease can be clinically detected. As a general rule, the earlier during embryonic development the mutation occurs, the greater the number of affected cells, and the greater the possibility of developing the disease. In diagnostic terms, not detecting variants in low mosaics, rather common with classical diagnostic methods, can lead to erroneous conclusions about the results of molecular tests, and therefore in the treatment and follow-up of patients 1 .
Familial hypercholesterolemia (FH, MIM: 143890) is a genetic disorder characterized by an elevation in total cholesterol (TC) and low-density lipoproteins-cholesterol (LDL-C) leading to premature cardiovascular disease 2 . The worldwide prevalence of FH has been estimated in 1/200-300 3, 4 and the main cause is the presence of pathogenic variants in the low density lipoprotein receptor gene (LDLR, MIM: 606945) which is involved in the LDL uptake. Up to date, more than 1700 variants have been reported in the LDLR gene and around 81% were classified as pathogenic or likely pathogenic 5 . Almost all types of variants have been described in LDLR being the missense the most frequent ones. Splicing variants, small and gross deletions and insertions have been described as well.
The increase in the number of reported variants in LDLR is due to the implementation of screening strategies to early detection of patients with FH and to the development of new molecular strategies. Conventional method for molecular diagnosis of FH is Sanger sequencing but due to its cost and time consuming, other methodologies have been developed such as the arrays-based methods 6 . The arrays methods are tailored to the most frequent mutations but this is a limitation because the less frequent or new variants are not detected which is an important methodology limitation. With the introduction of new technologies such as next generation sequencing (NGS), the success of the molecular diagnosis rate has increased. Despite this fact, a great number of patients remain without genetic confirmation. Traditionally, most of these patients are further classified as probably having a polygenic hypercholesterolemia.
Herein, we report a case of mosaicism in the LDLR gene in a patient with familial hypercholesterolemia.
Patients and Methods
The proband is a man 57 years old referred to our reference laboratory for genetic testing in and therefore, determine the final phenotype in the affected patient as well as the patterns of disease reoccurrence within families. Several biological specimens can be tested to detect mosaicism. In this study, we have analyzed two types of specimens, blood and saliva.
Although the liver is the target tissue for molecular diagnosis of hypercholesterolemia, since it is the main organ responsible for lipid homeostasis, it is not justified to obtain such a type of sample for genetic analyses due to the invasive nature of sampling. In any case, we assert that the proband´s liver is affected to such an extent grade conferring the patient with hypercholesterolemia phenotype. The proband´s germline tissue is also affected since two of his children are carriers of the pathogenic variant in a heterozygous form. Other pathologies present only in the form of mosaicism and are not heritable, probably because they are incompatible with life in germinal form. As an example we have the PIK3CA related overgrowth spectrum (PROS) 9 or the McCune-Albright syndrome. A third form of mosaicism is the one causing germline mosaic disorders, in which dominant pathologies occur in several children of phenotypically healthy parents, due to the presence of a mutation in the germline tissue of one of the parents. The most reported pathology with this type of mechanism is osteogenesis imperfecta type II 8 .
The mosaic variant in the LDLR gene presented in this work belongs to the group of mosaicisms in dominant genes. However, in addition to the somatic mosaicism, the patient transmitted the variant to two of his children, so his germ cells must be affected. This combination between somatic mosaicism and germinal mosaicism is known as gonosomal mosaicism.
The case described here confirms and highlights the fact that mosaicism does not always occur in clinically easily identifiable disorders. Therefore, we consider that in the FH the molecular confirmation of a mosaic pathogenic variant is especially useful in those patients with LDL-c borderline, and allows cascade screening in the family to further establish lifestyle changes or medication for early cardiovascular prevention. Although heterozygous FH frequency is around 1/200-250, a minor fraction of them is identified 10 , for this reason improving the molecular detection is of great interest. The use of new technologies such as the high-throughput deep sequencing allows the detection of mosaics. As we describe in our study it is possible that mosaicism can explain some of the cases of patients without molecular confirmation. This phenomenon can be suspected specially in those molecular unconfirmed cases with strong familial segregation, even more when less sensitive methods for analysis were previously used. Even if NGS was used for molecular diagnosis of FH, the bioinformatic treatment of the data should consider the possibility of a mosaicism so that these types of variants are not filtered prior to the variant calling. For example, in routine laboratories, a common variant call ratio used for filtering variants leaves out those that not reach the 20% of the reads. Therefore, the bioinformatics algorithms used for routine analysis need to improve in order to better detect mosaicism. Recent publications have addressed this topic 11 . On the other hand, another aspect to take into account is the reading depth usually used. Improving the deep coverage up to 1000x will increase the ability to detect low-level mosaicism. However, at present a relatively high cost of the test may be a major limitation for large-scale application of this approach in diagnostic laboratory.
Something that will probably be solved soon with the technological advances in the NGS platforms.
Sanger sequencing has been the gold standard technology used in most laboratories but it fails to identify cases of mosaicism. It is difficult to detect when the grade of mosaicism is low. Sanger sequencing possess less sensitivity compared with massive sequencing in detecting mosaicism. Recent publications state that the use of sanger sequencing is not adequate to validate NGS findings specially when the last one shows good quality parameters such as a good coverage of reads and quality [12] [13] [14] . The authors state that the use of sanger validation should be restricted for those cases in which the result of NGS has a serious implication for the probands and their families 12 .
With the extensive use of massive sequencing techniques more genes are screened routinely providing ever more information. With adequate tools to process the information, it is possible to explore not only the main genes responsible for FH but other candidate genes. In our experience, certain patients remitted to our laboratory because suspicious of FH have genetic variants in other genes involved in cholesterol metabolism. It is possible that these candidate genes could explain the lipid disturbances in these patients, and mosaicism could also be present in them. *control sample Figure 3 . The figure shows the results of NGS, Sanger sequencing and pyrosequencing analysis performed in blood and saliva samples. NGS analysis of blood samples show the reads with the pathogenic variant in the proband and his daughter. Alamut software was used to visualize BAM file. Sanger sequencing corresponding to exon 13 of the LDLR shows that the variant is hardly detected in the proband whereas it is clearly detected in his daughter. Pyrosequencing analysis of proband and daughter blood shows approximately 20% and 50% of pathogenic variant, respectively. Saliva sample from the proband was analyzed using the same three technologies. NGS sequencing and pyrosequencing analysis showed a mosaic of 8% and 18% of the pathogenic variant respectively, whereas Sanger sequencing hardly shows the variant.
